NCT-503 是一种能够透过血脑屏障的非竞争型 PHGDH 抑制剂,对人源 PHGDH 的 IC50 为 2.5 μM,可在不降低其蛋白表达的前提下减少葡萄糖来源的丝氨酸生成及一碳单位向核苷酸的掺入,并通过调节血糖、胰岛素水平及改善葡萄糖耐量来预防高硒诱导的小鼠胰岛素抵抗,还能抑制过表达 PHGDH 肿瘤的生长,可应用于胰岛素抵抗和乳腺癌的相关研究。
产品编号: MS-P66812 纯度: 99.69% CAS No.: 1916571-90-8 分子式: C20H23F3N4S 分子量: 408.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价
1g
询价
询价
5g
询价
询价

产品描述

NCT-503 是一种能够透过血脑屏障的非竞争型 PHGDH 抑制剂,对人源 PHGDH 的 IC50 为 2.5 μM,可在不降低其蛋白表达的前提下减少葡萄糖来源的丝氨酸生成及一碳单位向核苷酸的掺入,并通过调节血糖、胰岛素水平及改善葡萄糖耐量来预防高硒诱导的小鼠胰岛素抵抗,还能抑制过表达 PHGDH 肿瘤的生长,可应用于胰岛素抵抗和乳腺癌的相关研究。

生物实验数据

生物活性 NCT-503 is a brain-penetrant, non-competitive PHGDH inhibitor with an IC50 of 2.5 μM against human PHGDH that reduces glucose-derived serine synthesis and one-carbon unit incorporation into nucleotides without decreasing its protein expression, prevents high-selenium-induced insulin resistance in mice by modulating blood glucose and insulin levels and improving glucose tolerance, and inhibits the growth of tumors overexpressing PHGDH, making it applicable to research on insulin resistance and breast cancer.
IC50 & Target

IC50: 2.5 µM (PHGDH)

体外研究
(In Vitro)

NCT-503 (4 h/24 h,10 μM) 可与 MDA-MB-468 细胞中的 PHGDH 结合,减少葡萄糖来源的丝氨酸合成,抑制内源性和外源性丝氨酸的一碳单位掺入核苷酸,并增强 SHMT1 介导的一碳单位消耗;C234S PHGDHG12C 突变体可使 NCT-503 的效力降低约 3 倍。
NCT-503 (4 天) 可选择性抑制 PHGDH 依赖型人类癌细胞系 (MDA-MB-468、BT-20、HCC70、HT1080、MT-3) 的活力,其 EC50 值为 8-16 μM,而对 PHGDH 非依赖型细胞系仅表现出极低毒性或无毒性。

Cell Viability Assay

Cell Line: PHGDH-dependent (MDA-MB-468, BT-20, HCC70, HT1080, MT-3) and PHGDH-independent (MDA-MB-231, ZR-75-1, SK-MEL-2) human cancer cell lines
Concentration: Dose-response concentrations
Incubation Time: 4 days
Result: Exhibited EC50 values of 8-16 μM for PHGDH-dependent cell lines.
Showed a 6- to 10-fold higher EC50 for MDA-MB-231 cells.
Showed no toxicity towards other PHGDH-independent cell lines.
体内研究
(In Vivo)

NCT-503 (30 mg/kg;腹腔注射;每周 2 次;持续 5 个月) 可有效预防雄性 C57BL/6J 小鼠中高硒诱导的胰岛素抵抗,具体表现为空腹血糖恢复正常、葡萄糖耐量与胰岛素敏感性提升、血浆胰岛素水平降低,以及胰腺组织中 PI3K-AKT-mTOR 通路活性恢复,同时可强效抑制肝脏、肌肉与胰腺组织中的 PHGDH 酶活性。
NCT-503 (40 mg/kg;腹腔注射;每日一次;持续 24 天) 可在 NOD.CB17-Prkdcscid/J 小鼠中选择性抑制依赖 PHGDH 的 MDA-MB-468 原位乳腺癌异种移植物的生长并诱导其坏死,且不会导致小鼠体重下降。
NCT-503 (30 mg/kg;腹腔注射;单次给药) 可在 MDA-MB-468 原位异种移植模型中作用于 PHGDH,减少葡萄糖来源的丝氨酸合成。

Animal Model: C57BL/6J (male, 4 weeks old, SPF status, high-selenium diet-induced insulin resistance model)
Dosage: 30 mg/kg
Administration: i.p.; twice weekly; 5 months
Result: Significantly reduced high-selenium-induced weight gain compared to the high-selenium alone group, with final body weight closer to the adequate-selenium control group.
Prevented the gradual increase in fasting blood glucose levels seen in the high-selenium alone group, with levels remaining near those of the adequate-selenium control group by the fifth month.
Improved glucose tolerance, with significantly lower blood glucose levels compared to the high-selenium alone group during the glucose tolerance test.
Improved insulin sensitivity, with a reduced percentage change in blood glucose following insulin injection compared to the high-selenium alone group.
Significantly reduced plasma insulin levels compared to the high-selenium alone group.
Significantly increased plasma homocysteine levels compared to the high-selenium alone group.
Significantly reduced plasma serine levels compared to the high-selenium alone group.
Markedly reduced PHGDH enzyme activity in the liver, muscle, and pancreas compared to the high-selenium alone group; PHGDH activity was also significantly lower than in the adequate-selenium control group and the high-selenium + serine group.
Significantly reduced GPX1 and SELENOP protein expression in the liver compared to the high-selenium alone group and the high-selenium + serine group.
Significantly reduced GPX1 and SELENON protein expression in the muscle compared to the high-selenium alone group and the high-selenium + serine group.
Significantly reduced GPX1 protein expression in the pancreas compared to the high-selenium alone group and the high-selenium + serine group.
Increased PHGDH protein expression in the liver, muscle, and pancreas compared to the high-selenium + serine group.
Significantly increased SHMT1 protein expression in the pancreas compared to the high-selenium + serine group.
Significantly increased mTOR protein expression in the pancreas compared to the high-selenium alone group.
Significantly increased phosphorylated Akt (Ser-473 and Thr-308) protein expression in the pancreas compared to the high-selenium alone group.
Animal Model: NOD.CB17-Prkdcscid/J (female, 6-8 weeks old, orthotopic xenograft via injection of 500,000 MDA-MB-468 cells into the 4th mammary fat pad)
Dosage: 40 mg/kg
Administration: i.p.; daily; 24 days
Result: Reduced the growth and weight of PHGDH-dependent MDA-MB-468 xenografts.
Selectively increased necrosis in these xenografts.
Decreased production of glucose-derived serine in tumors.
Reached ~3 μM tumor exposure at the end of the experiment.
Prevented weight loss in mice during the 24-day treatment period.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 408.48
分子式 C20H23F3N4S
CAS No. 1916571-90-8

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (122.41 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

Ethanol 中的溶解度 : 13.33 mg/mL (32.63 mM; 超声助溶 (<60°C))

可选溶剂浓度1 mg5 mg10 mg25 mg
Ethanol / DMSO1 mM2.4481 mL12.2405 mL24.4810 mL61.2025 mL
5 mM0.4896 mL2.4481 mL4.8962 mL12.2405 mL
10 mM0.2448 mL1.2241 mL2.4481 mL6.1203 mL
15 mM0.1632 mL0.8160 mL1.6321 mL4.0802 mL
20 mM0.1224 mL0.6120 mL1.2241 mL3.0601 mL
25 mM0.0979 mL0.4896 mL0.9792 mL2.4481 mL
30 mM0.0816 mL0.4080 mL0.8160 mL2.0401 mL
DMSO40 mM0.0612 mL0.3060 mL0.6120 mL1.5301 mL
50 mM0.0490 mL0.2448 mL0.4896 mL1.2241 mL
60 mM0.0408 mL0.2040 mL0.4080 mL1.0200 mL
80 mM0.0306 mL0.1530 mL0.3060 mL0.7650 mL
100 mM0.0245 mL0.1224 mL0.2448 mL0.6120 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础